Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03802695 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Orca Biosystems.

Recruiting
Registry status
Phase 1
Development phase
300
Enrollment target
9
Study locations

NCT03802695 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Orca Biosystems. The registered enrollment target is 300 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (161% higher). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03802695, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Orca Biosystems.

RECRUITING
Registry status
Phase 1
Development phase
300 participants
Enrollment target
9
Study locations

Study Summary

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia

Interventions

  • BIOLOGICAL OrcaGraft (Orca-Q)

Study Locations (9)

California

  • City of Hope - Duarte
  • UC Davis - Sacramento
  • Stanford Health Care - Stanford

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Emory University - Atlanta

Kansas

  • The University of Kansas Hospital - Kansas City

Ohio

  • Ohio State University - Columbus

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Wisconsin

  • Froedtert Memorial Lutheran Hospital - Milwaukee

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2019-04-08
Est. Completion 2027-12
Phase Phase 1

Sponsor

Orca Biosystems

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03802695

The ClinicalTrials.gov registry entry for NCT03802695 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (161% higher). The listed sponsor is Orca Biosystems, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which OrcaGraft (Orca-Q) is the first listed.

NCT03802695 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT03802695 about?

NCT03802695 is a clinical study titled "A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies". This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

What is the current status of trial NCT03802695?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2019-04-08. Estimated completion is 2027-12.

What conditions does trial NCT03802695 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia.

What interventions are being tested in trial NCT03802695?

The interventions under investigation include: OrcaGraft (Orca-Q) (BIOLOGICAL).

Who is sponsoring clinical trial NCT03802695?

This trial is sponsored by Orca Biosystems, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03802695 being conducted?

This trial has 9 study locations across California, Florida, Georgia, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.